Kennedy Capital Management LLC Sells 23,750 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Kennedy Capital Management LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,017,666 shares of the biopharmaceutical company’s stock after selling 23,750 shares during the period. Kennedy Capital Management LLC owned approximately 0.85% of Catalyst Pharmaceuticals worth $21,239,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after purchasing an additional 390,116 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after purchasing an additional 151,495 shares during the period. Renaissance Technologies LLC increased its position in shares of Catalyst Pharmaceuticals by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company’s stock worth $56,477,000 after acquiring an additional 180,100 shares in the last quarter. Boston Partners increased its position in shares of Catalyst Pharmaceuticals by 1.3% during the fourth quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock worth $27,325,000 after acquiring an additional 16,601 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after acquiring an additional 79,182 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 6.3 %

CPRX opened at $22.74 on Thursday. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 3.31 and a beta of 0.79. The firm’s fifty day simple moving average is $22.68 and its two-hundred day simple moving average is $21.98. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $26.16.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CPRX shares. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Bank of America reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. Robert W. Baird boosted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and an average price target of $32.29.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.